Key result
Elevated proenkephalin levels independently predicted a higher risk of the 2-year composite of all-cause mortality and heart failure rehospitalization in patients with HFpEF (HR 1.45 per 1 SD increment).
Why the study?
Proenkephalin has prognostic utility in heart failure, but its prognostic utility and relationship to renal function, BMI, and diastolic dysfunction in HFpEF required investigation.
Does proenkephalin (PENK) level predict all-cause mortality and heart failure rehospitalisation in patients with heart failure with preserved ejection fraction (HFpEF)?
Cohort (n=522)
Yes
Does proenkephalin (PENK) level predict all-cause mortality and heart failure rehospitalisation in patients with heart failure with preserved ejection fraction (HFpEF)?
Hazard Ratio: 1.45 (95% CI 1.12–1.88)
p-value: p=0.005
In patients with HFpEF, elevated plasma proenkephalin (PENK) levels independently predict the 2-year composite outcome of all-cause mortality and heart failure rehospitalization.
PENK may refine HFpEF risk stratification; leaves open whether it guides therapy or improves outcomes.
BACKGROUND: Proenkephalin (PENK), a stable endogenous opioid biomarker related to renal function, has prognostic utility in acute and chronic heart failure. We investigated the prognostic utility of PENK in heart failure with preserved ejection fraction (HFpEF), and its relationship to renal function, Body Mass Index (BMI), and imaging measures of diastolic dysfunction. METHODS: In this multicentre study, PENK was measured in 522 HFpEF patients (ejection fraction > 50%, 253 male, mean age 76.13 ± 10.73 years) and compared to 47 age and sex-matched controls. The primary endpoint was 2-years composite of all-cause mortality and/or heart failure rehospitalisation (HF). A subset (n = 163) received detailed imaging studies. RESULTS: 0.635, - 0.741, - 0.275, 0.476, respectively, p < 0.0005). During 2 years follow-up 144 patients died and 220 had death/HF endpoints. Multivariable Cox regression models showed PENK independently predicted 2 year death/HF [hazard ratio (for 1 SD increment of log-transformed biomarker) HR 1.45 [95% CI 1.12-1.88, p = 0.005]], even after adjustment for troponin (HR 1.59 [1.14-2.20, p = 0.006]), and Body Mass Index (HR 1.63 [1.13-2.33, p = 0.009]). PENK showed no interaction with ejection fraction status for prediction of poor outcomes. Net reclassification analyses showed PENK significantly improved classification of death/HF outcomes for multivariable models containing natriuretic peptide, troponin and Body Mass Index (p < 0.05 for all). CONCLUSIONS: In HFpEF, PENK levels are related to BMI, and measures of diastolic dysfunction and are prognostic for all-cause mortality and heart failure rehospitalisation.
No takes yet. Share an insight, caveat, or question.
Kanagala et al. (2019) conducted a cohort in Heart failure with preserved ejection fraction (HFpEF) (n=522). Proenkephalin (PENK) vs. Lower PENK levels (per 1 SD increment) was evaluated on 2-year composite of all-cause mortality and/or heart failure rehospitalisation (HR 1.45, 95% CI 1.12-1.88, p=0.005). Elevated proenkephalin levels independently predicted a higher risk of the 2-year composite of all-cause mortality and heart failure rehospitalization in patients with HFpEF (HR 1.45 per 1 SD increment).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: